Effect of acupuncture treatment on post-stroke cognitive impairment: a randomized controlled trial

注册号:

Registration number:

ITMCTR2000003394

最近更新日期:

Date of Last Refreshed on:

2020-06-13

注册时间:

Date of Registration:

2020-06-13

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺治疗中风后轻度认知障碍的随机对照临床疗效研究

Public title:

Effect of acupuncture treatment on post-stroke cognitive impairment: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗血管性认知障碍的临床研究

Scientific title:

A clinical study of acupuncture treatment on vascular cognitive impairment

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000033801 ; ChiMCTR2000003394

申请注册联系人:

南茜

研究负责人:

杜宇征

Applicant:

Nan Xi

Study leader:

Du Yuzheng

申请注册联系人电话:

Applicant telephone:

+86 18722646195

研究负责人电话:

Study leader's telephone:

+86 13702088266

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

912418839@qq.com

研究负责人电子邮件:

Study leader's E-mail:

drduyuzheng@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市西青区昌凌路88号

研究负责人通讯地址:

天津市西青区昌凌路88号

Applicant address:

88 Changling Road, Xiqing District, Tianjin, China

Study leader's address:

88 Changling Road, Xiqing District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津中医药大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

TYLL2020[K]字 013

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

天津中医药大学第一附属医院医学伦理委员会

Name of the ethic committee:

The Ethic Committee of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/4/28 0:00:00

伦理委员会联系人:

张军平

Contact Name of the ethic committee:

Zhang Junping

伦理委员会联系地址:

天津市西青区昌凌路88号

Contact Address of the ethic committee:

88 Changling Road, Xiqing District, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津中医药大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

天津市西青区昌凌路88号

Primary sponsor's address:

88 Changling Road, Xiqing District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院

具体地址:

西青区昌凌路88号

Institution
hospital:

The First Teaching Hospital of University of traditional Chinese Medicine

Address:

88 Changling Road, Xiqing District

经费或物资来源:

天津市科技计划项目

Source(s) of funding:

Tianjin Science and Technology Project

研究疾病:

血管性认知障碍

研究疾病代码:

Target disease:

Vascular cognitive impairment

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

开展多中心、随机、对照的临床试验研究,评价“调神益智”针刺法治疗血管性轻度认知障碍的疗效,为针刺改善认知功能、延缓痴呆的进展获得高质量循证证据;从脑功能成像角度探索针刺治疗血管性认知障碍的中枢效应机制。

Objectives of Study:

A multicentric, randomized, controlled clinical trial is conducted to evaluate the efficacy of "Tiao Shen Yi Zhi" acupuncture therapy on vascular mild cognitive impairment, so as to obtain high-quality evidence-based evidence for improving cognitive function and delaying the progression of dementia by acupuncture.To explore the central effect mechanism of acupuncture in the treatment of vascular cognitive impairment from the perspective of brain functional imaging.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 脑梗死发病6个月内; 2. 神经心理学测验证实存在认知损害,即1个及以上认知域的确定损害或2个及以上认知域的临界损害,不符合痴呆诊断标准。蒙特利尔认知评估量表(MoCA)<26分;简易智能精神状态量表(MMSE):文盲(未受教育)>17分,小学(教育年限≤6年)>20分,中学以上(教育年限>6年)>24分; 3. 年龄在18~75岁; 4. 日常生活基本自理:Barthel指数≥60分; 5. 患者或家属签署知情同意书,配合治疗者。

Inclusion criteria

1. Patients with cerebral infarction within 6 months; 2. Neuropsychological tests show that the patients with cognitive impairment, i.e. the confirmed impairment of one or more cognitive domains or the critical impairment of two or more cognitive domains, do not meet the diagnostic criteria of dementia. Montreal Cognitive Assessment Scale (MoCA) < 26 points; MMSE: illiterate (uneducated) > 17 points, primary school (education period <= 6 years) > 20 points, middle school and above (education period > 6 years) > 24 points; 3. Patients aged 18-75 years; 4. Patients with basic self-care in daily life: Barthel Index >= 60 points; 5. Patients or family members sign informed consent to cooperate with the treatment.

排除标准:

1. 本次脑梗死发病前存在认知障碍者; 2. 既往曾服用胆碱酯酶抑制剂、胞磷胆碱钠等可改善认知的药物或接受改善认知的针刺治疗者; 3. 因精神疾患、认知或情绪障碍无法完成本研究者; 4. 有严重心脏、消化、泌尿系统等其他威胁生命的严重疾病; 5. 患者无长期共同生活或照料者; 6. 妊娠、计划妊娠或哺乳期妇女; 7. 近1个月参加与针刺或认知障碍相关临床试验者。

Exclusion criteria:

1. Patients with cognitive impairment before the onset of this cerebral infarction; 2. Patients who have taken cholinesterase inhibitors, citicoline sodium and other cognitive improving drugs or received cognitive improving acupuncture treatment before; 3. Patients who are unable to complete the study due to mental disorders, cognitive or emotional disorders; 4. Patients with serious heart, digestive, urinary and other life-threatening serious diseases; 5. The patient has no long-term common life or care; 6. Pregnant, planned or lactating women; 7. Patients who participated in clinical trials related to acupuncture or cognitive impairment in the past 1 month.

研究实施时间:

Study execute time:

From 2018-10-01

To      2021-09-30

征募观察对象时间:

Recruiting time:

From 2020-06-20

To      2021-01-01

干预措施:

Interventions:

组别:

针刺组

样本量:

120

Group:

Acupuncture group

Sample size:

干预措施:

“调神益智”针刺治疗

干预措施代码:

Intervention:

“Tiaoshen Yizhi” acupuncture therapy

Intervention code:

组别:

等待治疗组

样本量:

120

Group:

Waiting treatment group

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

conventional therapy

Intervention code:

组别:

假针刺组

样本量:

120

Group:

Sham-acupuncture group

Sample size:

干预措施:

非经非穴浅刺

干预措施代码:

Intervention:

Non-meridian non-acupoint shallow acupuncture treatment

Intervention code:

样本总量 Total sample size : 360

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

吉林

市(区县):

长春

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

长春市中医院

单位级别:

三级甲等

Institution/hospital:

Changchun Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Tianjin University of traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山西省

市(区县):

长治市

Country:

China

Province:

Shanxi

City:

Changzhi

单位(医院):

山西省长治市中医研究所附属医院

单位级别:

三级乙等

Institution/hospital:

Affiliated Hospital of Changgzhi Institute of Traditional Chinese Medicine

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

内蒙古

市(区县):

包头

Country:

China

Province:

Neimenggu

City:

Baotou

单位(医院):

内蒙古科技大学包头医学院第二附属医院

单位级别:

三级甲等

Institution/hospital:

The Second Teaching Hospital of Inner Mongolia University of Science and Technology Baotou Medical College

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南

市(区县):

长沙

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

湖南省长沙市中医医院

单位级别:

三级甲等

Institution/hospital:

Hunan Province Changsha Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

痴呆发生率

指标类型:

主要指标

Outcome:

Incidence of dementia

Type:

Primary indicator

测量时间点:

入组时、治疗3个月结束时、随访3个月、随访6个月

测量方法:

Measure time point of outcome:

At enrollment, at the end of 3 months of treatment, 3 months of follow-up, and 6 months of follow-up

Measure method:

指标中文名:

不良反应发生率

指标类型:

副作用指标

Outcome:

Incidence of adverse reactions

Type:

Adverse events

测量时间点:

随时记录

测量方法:

Measure time point of outcome:

Records at any time

Measure method:

指标中文名:

精神症状评价(NPI)

指标类型:

次要指标

Outcome:

Evaluation of mental symptoms

Type:

Secondary indicator

测量时间点:

入组时、治疗3个月结束时、随访3个月、随访6个月

测量方法:

Measure time point of outcome:

At enrollment, at the end of 3 months of treatment, 3 months of follow-up, and 6 months of follow-up

Measure method:

指标中文名:

人β-淀粉样蛋白

指标类型:

附加指标

Outcome:

Amyloid beta ( Aβ)

Type:

Additional indicator

测量时间点:

入组时、治疗3个月结束时

测量方法:

Measure time point of outcome:

At enrollment, at the end of 3 months of treatment

Measure method:

指标中文名:

认知功能的恢复情况

指标类型:

主要指标

Outcome:

Recovery of cognitive function

Type:

Primary indicator

测量时间点:

入组时、治疗3个月结束时、随访3个月、随访6个月

测量方法:

Measure time point of outcome:

At enrollment, at the end of 3 months of treatment, 3 months of follow-up, and 6 months of follow-up

Measure method:

指标中文名:

日常生活活动能力评价(FAQ)

指标类型:

次要指标

Outcome:

Ability evaluation of daily activities

Type:

Secondary indicator

测量时间点:

入组时、治疗3个月结束时、随访3个月、随访6个月

测量方法:

Measure time point of outcome:

At enrollment, at the end of 3 months of treatment, 3 months of follow-up, and 6 months of follow-up

Measure method:

指标中文名:

生活质量评价(WHOQOL-BREF)

指标类型:

次要指标

Outcome:

Quality of Life evaluation

Type:

Secondary indicator

测量时间点:

入组时、治疗3个月结束时、随访3个月、随访6个月

测量方法:

Measure time point of outcome:

At enrollment, at the end of 3 months of treatment, 3 months of follow-up, and 6 months of follow-up

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

利用中央随机方法,按1:1:1的比例将入组受试者随机分入针刺组、假针刺组和等待治疗组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Using the central randomization method, enrolled subjects are randomly divided into acupuncture group, sham acupuncture group and waiting treatment group at a ratio of 1:1:1.

盲法:

对参试者施盲,疗效评价由不知分组情况的研究人员负责;统计由不参与本研究的第三方人员负责。

Blinding:

Blind method for subjects, outcome evaluators and statisticians.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Not stated

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Not stated

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above